Cel-Sci (CVM) vs INmune Bio (INMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
INmune Bio (INMB) has outperformed Cel-Sci (CVM) over the past year, losing 45.2% versus a loss of 80.7%. Over five years, INMB leads with a -93.8% price change compared with -99.6% for CVM. INmune Bio is the larger company by market cap ($25.6 million vs $21.3 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CVM | INMB |
|---|---|---|
| Share price | $1.21 | $0.827 |
| Market cap | $21.28M | $25.60M |
| 1-day change | -17.69% | -7.50% |
| YTD return | -77.00% | -46.99% |
| 1-year return | -80.67% | -45.23% |
| 5-year return | -99.61% | -93.80% |
| EPS (TTM) | $-1.69 | $-0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $50.00K |
| Revenue growth (YoY) | — | +257.14% |
| Net income (latest FY) | $-25.41M | $-45.93M |
| Operating margin | — | -94766.00% |
| Net margin | — | -91866.00% |
| 52-week high | $7.80 | $2.60 |
| 52-week low | $0.89 | $0.8189 |
| Distance from 52-week high | -84.49% | -68.19% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +933.06% | +746.43% |
| Average volume | 231.46K | 338.47K |
| Shares outstanding | 17.59M | 30.96M |
| Employees | — | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INMB has outperformed CVM by 35.4 percentage points over the past year.
About Cel-Sci
CVM stock →CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About INmune Bio
INMB stock →INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees
CVM vs INMB FAQ
Which is bigger, Cel-Sci or INmune Bio?
INmune Bio (INMB) is larger, with a market capitalization of $25.60M compared with $21.28M for Cel-Sci (CVM).
Which stock has performed better over the past year, CVM or INMB?
INMB returned -45.23% over the past 12 months, compared with -80.67% for CVM (price return, excluding dividends). Past performance does not predict future results.
Are Cel-Sci and INmune Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.